ReviewJournal of medical virology2026
Hijacking the Host: Post-Translational Modifications as Molecular Switches in HIV Persistence and Immune Evasion.
Review in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Achieving a functional cure for HIV-1 requires dismantling the molecular circuits that enable viral latency and immune evasion. Beyond transcriptional silencing and epigenetic repression, post-translational modifications (PTMs) of host and viral proteins operate as dynamic molecular switches that regulate all phases of the viral life cycle, from integration and transcription to immune recognition and reservoir maintenance. This review synthesizes recent discoveries across major PTM types, including phosphorylation, ubiquitination, SUMOylation, acetylation, methylation, glycosylation, and ISGylation, and highlights how these modifications modulate intrinsic and adaptive immunity, chromatin state, protein turnover, and viral RNA metabolism. We further explore how targeting PTM networks offers a promising therapeutic avenue to reverse latency, destabilize reservoirs, or enhance immune clearance with minimal off-target activation. By surveying the HIV-PTM regulatory landscape, we highlight actionable nodes that can inform next-generation strategies for durable remission and immune reprogramming.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.